Meeting
2023 ASCO Annual Meeting
Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: Comparison and combination of cell and cell-free platforms.
Authors
Giuseppe Di Caro
Epic Sciences, San Diego, CA
Giuseppe Di Caro , Ernest Lam , David Bourdon , Tatjana Singer , Kandra Horne , Megan Slade , Rick Wenstrup , Lee S. Schwartzberg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Circulating Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3061)
DOI
10.1200/JCO.2023.41.16_suppl.3061
Abstract #
3061
Poster Bd #
259
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa).
First Author: Qiang Zhang
Poster
2019 ASCO Annual Meeting
Genomic somatic alterations of human epidermal growth factor-2 (HER2) gene: A pan-cancer analysis.
First Author: Xinhua Zhu
Poster
2018 ASCO Annual Meeting
Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).
First Author: Huiping Li
Poster
2023 ASCO Breakthrough
Comparisons between HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295 ER+ HER2- breast cancer.
First Author: Sung Gwe Ahn